MAPKeeper 301

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Dec 17, 2025 → Oct 30, 2026

Cited window

Jan 7, 2026 → Oct 30, 2026

Retrieved

Nov 1, 2026

Title

A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)

Registry

NCT07562152

Study IDs

IMM1104-301

Sponsor

Immuneering Corporation

Design

Phase 3 · Interventional, randomized, parallel

Status

Recruiting

Enrollment

510 estimated

Registered

2026-05-01

Start

2026-06-05 actual

Primary completion

2028-06 estimated

Primary endpoint

Overall Survival

Interventions

3 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Not yet captured in this edition: a remark on first-line pancreatic cancer efficacy evidence and planned pivotal trial initiation.
• –Not yet captured in this edition: a remark on the start of patient dosing in the pivotal metastatic pancreatic cancer trial.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –103 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed do not represent all HCPs or all public discussion. Some relevant passages were not fully assessed, and unnamed references or wording variants may be missing; absence of a view is not evidence that nobody expressed it.
• –The material mixes documented clinician commentary, authors whose clinical roles are not established, company statements and investment-oriented interpretations. These categories cannot be pooled into an HCP consensus.
• –Similar posts, reposts and substantially overlapping educational videos are not independent opinions. A confirmed identifier or professional association does not increase the truth or evidentiary weight of a view.
• –No exact-trial outcomes publication or protocol was available. Formal eligibility detail, amendments and regulatory assertions could not be independently checked from those documents.
• –Most numerical efficacy and safety discussion concerns earlier-phase studies, with historical comparators and differing cohorts, follow-up or reported values. It must not be presented as MAPKeeper 301 results.
• –Some July educational-video comments have no identified speaker. Attribution in a separate upload does not establish who spoke those passages.
• –Accounts differ in response estimates, safety attribution and anticipated trial timing. The report preserves those differences rather than choosing a preferred version.
• –Approval characterizations and unusual drug names are preserved as the authors expressed them. They are not independently confirmed regulatory facts.
• –Mechanistic explanations for weight preservation, post-progression survival and failures of other development programs remain attributed hypotheses, not established causal findings.

How reports are built and checked: Methods.

Last checked for new commentary Nov 1, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "MAPKeeper 301" (NCT07562152), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "mapkeeper-301-07562152". If you cannot make requests, read https://www.erudio.com/reports/mapkeeper-301-nct07562152.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT07562152", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct07562152 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/mapkeeper-301-nct07562152.json
curl https://www.erudio.com/reports/mapkeeper-301-nct07562152.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "mapkeeper-301-07562152" })